When I began practicing obesity medicine nearly 20 years ago, it was difficult for my patients to attain significant long-term weight loss without metabolic and bariatric surgery.
Any company hoping to make headway in the market for obesity therapies will need deep pockets, so it’s an encouraging sign that start-up Metsera has launched with an impre
Eli Lilly’s diabetes and obesity therapy tirzepatide could find a use as a treatment for obstructive sleep apnoea (OSA) after hitting the mark in a pair of phase 3 trials.
There is no evidence of an increased risk of suicidal or self-injurious thoughts and actions with GLP-1 agonists used to treat diabetes and obesity, according to the EU me
Medicare has loosened restrictions on the reimbursement of obesity drugs, thanks to clinical data showing they can improve cardiovascular outcomes, but their price could b
GSK looks like it is starting to show the benefit of a revamp of its business under chief executive Emma Walmsley, with recent product launches driving a 10% rise in sales
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.